Vincerx Pharma Reports Second Quarter 2024 Financial Results

Core Insights - Vincerx Pharma is advancing its clinical programs, with data from its Phase 1 studies of ADC VIP943 expected by the end of Q4 2024 and SMDC VIP236 by the end of Q3 2024 [1][2]. Clinical Programs and Milestones - VIP943 is a CD123-targeted ADC designed to improve efficacy and reduce toxicities, with data for patients with relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia expected by the end of Q4 2024 [3]. - VIP236 is a first-in-class SMDC that delivers an optimized camptothecin payload directly to tumor tissues, with data anticipated by the end of Q3 2024 [4]. - Enitociclib, a selective CDK9 inhibitor, is in a Phase 1 study evaluating its combination with venetoclax and prednisone for diffuse large B-cell lymphoma and peripheral T-cell lymphoma [5]. - VIP924, another ADC targeting CXCR5, is planned for evaluation in B-cell malignancies, with an IND application expected in early 2026 [6]. Financial Results - As of June 30, 2024, Vincerx had approximately $16.3 million in cash and equivalents, up from $5.1 million as of March 31, 2024, and expects this capital to support operations through the end of 2024 [7]. - Research and development expenses for Q2 2024 were approximately $3.8 million, a decrease from $8.2 million in Q2 2023, primarily due to reduced research and manufacturing costs [7]. - General and administrative expenses for Q2 2024 were approximately $3.6 million, slightly down from $3.8 million in Q2 2023 [7]. - The net loss for Q2 2024 was approximately $1.8 million, or $0.05 per share, compared to a net loss of approximately $11.6 million, or $0.54 per share, in Q2 2023 [7][15].